Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Shih-Jen Liu a, Chih-Hsiang Leng a, Shu-pei Lien a, Hsiang-Yun Chi b, Chiung-Yi Huang a, Chang-Ling Lin b, Wei-Cheng Liana, b, Chi-Ju Chen c, Shie-Liang Hsieh c, Pele Chong a, ∗

a Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli, Taiwan
b Center for Disease Control, Taipei, Taiwan
c Department of Microbiology and Immunology, National Yang Ming University, Taipei, Taiwan

Received 9 August 2005; received in revised form 30 December 2005; accepted 21 January 2006
Available online 8 February 2006

Abstract

The recombinant nucleocapsid (rN) protein of the coronavirus (CoV) responsible for severe acute respiratory syndrome (SARS) was cloned and expressed in Escherichia coli, extracted from cell lysates containing 6 M urea, then purified by Ni 2+-affinity chromatography. In animal immunogenicity studies, we found that most anti-rN protein antibodies were IgG2a in BALB/c mice vaccinated with rN emulsified in Montanide ISA-51 containing the synthetic oligodeoxynucleotide, CpG. In contrast, anti-rN protein antibodies of mice immunized with rN protein in PBS were found to mainly be IgG1. These results indicated that ISA-51/CpG-formulated rN protein was dramatically biased toward a Th1 immune response. To identify the B-cell immunodominant epitopes of the rN protein in the mouse and monkey, the reactivities of antisera raised against purified rN proteins formulated in ISA-51/CpG were tested with a panel of overlapping synthetic peptides covering the entire N protein sequence. Three immunodominant linear B-cell epitope regions were mapped to residues 166–180, 356–375, and 396–410 of the rN protein. When the reactivities of these peptides were screened with human sera from five SARS patients, peptides corresponding to residues 156–175 reacted strongly with sera from two of the SARS patients. These results indicated that the region around residues 156–175 of the N protein is immunogenic in the mouse, monkey, and human. We found that peptides corresponding to residues 1–30, 86–100, 306–320, and 351–365 contained murine immunodominant T-cell epitopes. To identify functional CTL epitopes of the N protein, BALB/c mice were immunized with peptides containing the H-2Kd CTL motif emulsified in adjuvant ISA-51/CpG. Using an IFN-γ secretion cell assay and analysis by flow cytometry, peptides containing residues 81–95 were found to be capable of stimulating both CD4+ and CD8+ cell proliferation in vitro. We also observed that peptides corresponding to residues 336–350 were capable of stimulating IFN-γ production in T-cell cultures derived from peripheral blood mononuclear cells (PBMCs) of macaques immunized with the rN protein emulsified in ISA/CpG adjuvant. Our current results together with those of others suggest that some immunodominant B-cell and T-cell epitopes are conserved in the mouse, monkey, and human. This information is very important for the development SARS diagnostic kits and a vaccine.

Keywords: SARS CoV; Epitopes; Vaccine; Nucleocapsid protein

1. Introduction

A newly emerging infectious disease caused by the severe acute respiratory syndrome-associated coronavirus (SARS CoV) had significant economic impacts in countries affected by the disease outbreak in 2003–2004. The lack of efficient treatments and prevention means the possibility exists for SARS to return in the future. In addition, high-risk populations such as laboratory and hospital workers need effective...
SARS vaccines for protection. Unfortunately, recent reports have shown that inactivated coronavirus vaccines in a cat model might worsen the disease rather than prevent it [1]. Furthermore, the SARS virus may cause mild liver inflammation in ferrets, and the damage was much more serious if animals were first given a candidate SARS vaccine based on the vaccinia virus [2]. Yang et al. [3] also found that antibodies against SARS CoV S protein enhanced the entry of virus in vitro cell culture studies. Therefore, in order to generate safe and effective SARS vaccines, we urgently need greater understanding of the immunological responses of vaccine candidates in different animal models.

The N protein of the feline infectious peritonitis virus (FIPV) has been used as subunit vaccines to induce protective immunity and to prevent the progression of diseases in a cat model [4]. The literature indicates that immunization of DNA plasmids that encode the N protein of the Ebola virus and influenza virus elicits protective antigen-specific cytotoxic T lymphocyte (CTL) responses [5–7]. In avian coronaviruses, N protein-specific T-cell responses were shown to generate protective immunity [8]. These results indicate that a good N protein vaccine candidate should elicit strong cellular immune responses. The N protein of SARS CoV is 422 amino acids long and highly conserved (99%) within different isolates, but it shares only 20–30% amino acid homology with the N proteins of other coronaviruses [9]. In fact, the DNA vaccine candidate encoding the N protein of the SARS CoV fused with calreticulin (CRT) was shown to induce potent humoral and cellular immune responses in a mouse model, and inhibited replication of the recombinant vaccinia virus that expressed the N protein in vivo [10]. We therefore focused on the N protein of the SARS CoV as the target antigen for subunit vaccine development.

With an eye toward clinical applications, we selected two potential adjuvants in clinical use that have been shown to be strong cellular immune response inducers: Montanide ISA-51 and the immunostimulating oligonucleotide, CpG [11]. ISA-51 and CpG were used to emulsify the rN protein as vaccine candidates for mouse and macaque immunogenicity studies. In the present study, we report that (1) ISA-51/CpG-formulated rN protein was dramatically biased toward the Th1 immune response; (2) the immunodominant B- and T-cell epitopes of the N protein were present in both BALB/c mice and macaques; (3) conserved immunodominant B-cell epitopes were identified in mice, macaques, and SARS patients; (4) N protein-specific CD8+ cells could be induced by ISA-51/CpG formulated with either the rN protein or synthetic peptides containing the H-2Kb CTL epitope motif.

2. Materials and methods

2.1. Production of rN protein

Recombinant SARS CoV N protein (rN) containing a N-terminal His tag gene was cloned into the pRSETA vector (Invitrogen, Carlsbad, CA, USA) for protein expression. The plasmid was transformed into an Escherichia coli BL21(DE3)Gold (Stratagene, Cedar Creek, TX, USA) host strain and incubated at 32 °C overnight. The expression of rN was induced with 0.5 mM of isopropyl β-thiogalactoside (IPTG) for 3 h, then cells were harvested by centrifugation (8000 × g for 20 min), and cell pellets were re-suspended in 100 ml of homogenate buffer (20 mM Tris–Cl (pH 8.0), 500 mM NaCl, 10% glycerol, 50 mM sucrose, and 10 mM imidazole). After disruption using a French Press (Constant Systems, Daventry, UK) at 186 Mpa, cell lysates were clarified by centrifugation (80,000 × g for 60 min). Most of the target protein was extracted from the pellet with 8 M urea in homogenate buffer and loaded into 1 ml of Ni-NTA resin (Qagen, San Diego, CA, USA). The resin was washed with the same buffer, and the target protein was purified by changing the pH value. After further washing with pH 6.3 and 5.9 homogenate buffers and 8 M urea, the rN was eluted from the resin using pH 4.5 homogenate buffer and 8 M urea, then the purified rN was refolded by dialysis against phosphate-buffered saline (PBS). The purified rN was stored at −20 °C in PBS with 10% glycerol for further studies.

2.2. SDS–PAGE and Western blot analysis

When analyzing samples by SDS–PAGE, 10 μl of samples were mixed with an equal volume of the sample buffer (63 mM Tris–HCl (pH 6.8), 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, and 0.002% bromophenol blue) and heated in boiling water for 3 min. The samples (5–50 μg protein per lane) were separated on a 10% SDS–PAGE, then electrophoretically transferred from the gel to a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA) at 302 mA for 40 min. The membrane was blocked overnight with 5% non-fat milk in PBS containing 0.05% Tween-20 (PBST) at 4 °C. After washing with PBST, the blot was incubated at room temperature for 1 h with a mouse anti-His antibody (1:1500 dilution, Amersham Biosciences, New Territories, HK). After extensive washing with PBST then incubation for 1 h with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:5000, Bethyl Laboratories, Montgomery, TX, USA), the blot was developed with 0.2 mM DAB (3,3′-diaminobenzidine tetrahydrochloride, Sigma, St. Louis, MO, USA). After development for 2–3 min, the blot was washed with distilled water to stop the reaction.

2.3. Animals for immunogenicity studies

Six-to-eight-week old female BALB/c mice were obtained from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). All mice were housed at the Animal Technology Institute Taiwan (ATIT, Miaoli, Taiwan) animal facility. Monkeys (Formosan macaques, Macaca cyclopis) were maintained in accordance with institutional animal care protocols of the Center of Disease Control, Taipei, Taiwan.
2.4. Peptide synthesis

Peptides derived from the SARS CoV N protein sequence were synthesized as 15-mer fragments with 10-amino-acid overlap that covered the entire N protein sequence of the Urbani strain (Kelowna, Taipei, Taiwan); peptides were dissolved in 5% DMSO at 2 mg/ml. Two CTL epitopes, QFKD-Urbani and VWV ATEGAL, produced from the N protein with the BABL/c (H-2K^k) mouse I binding motif, were predicted by a computer-based program on the website of the Bioinformatics and Molecular Analysis Section (Bethesda, MD, USA) [12].

2.5. Production of N protein-specific antisera

Mice were immunized subcutaneously with 50 µg of rN protein emulsified in incomplete Freund’s adjuvant (IFA) or Montanide ISA-51 (Seppic, Paris, France) with 50 µg of the CpG oligonucleotide (TCG TCG TTT TGT CGT TTT GTC TT). Mice received two booster doses of the immunogen, one each at 2 and 4 weeks later. Blood samples were collected every 2 weeks post-immunization. For T-cell analysis, mice were sacrificed at 7 days after the final immunization. In the pooled peptides groups, all peptides (Table 2) were synthesized as 15-mer fragments with 10-amino-acid overlaps, and immunized subcutaneously. For the monkey experiments, the peptides (Table 2; 10 µg each) were emulsified in ISA-51 plus 50 µg of the CpG oligonucleotide (ISA/CpG), and immunized subcutaneously. On day 7 after the final immunization, mice were sacrificed to harvest their spleens. Erythrocyte-depleted splenocytes were cultured in vitro with 5 µg/ml of pooled peptide or individual peptide that covered all of the N protein amino acid plates for 5 h. IFN-γ-secreting cells were detected with a Mouse IFN-γ Secretion Assay Detection Kit (Miltenyi Biotec., Gladbach, Germany). In brief, 1 × 10^6 splenocytes were harvested and labeled with an IFN-γ capture antibody for 5 min at 4 °C. Afterwards, cells were transferred into 37 °C warm medium for 45 min, then washed twice, and stained with phycoerythrin (PE)-conjugated IFN-γ detection reagent, and fluorescein isothiocyanate (FITC)-conjugated anti-CD8 or anti-CD4 antibodies. After washing, cells were collected and analyzed on a FACSCalibur instrument with CellQuest software. Dead cells were gated by 1 µg/ml propidium iodide.

2.8. IFN-γ Secretion cell staining and flow cytometric analysis

On day 7 after the final immunization, mice were sacrificed to harvest their spleens. Erythrocyte-depleted splenocytes were cultured in vitro with 5 µg/ml of pooled peptide or individual peptide that covered all of the N protein amino acid plates for 5 h. IFN-γ-secreting cells were detected with a Mouse IFN-γ Secretion Assay Detection Kit (Miltenyi Biotec., Gladbach, Germany). In brief, 1 × 10^6 splenocytes were harvested, and labeled with an IFN-γ capture antibody for 5 min at 4 °C. Afterwards, cells were transferred into 37 °C warm medium for 45 min, then washed twice, and stained with phycoerythrin (PE)-conjugated IFN-γ detection reagent, and fluorescein isothiocyanate (FITC)-conjugated anti-CD8 or anti-CD4 antibodies. After washing, cells were collected and analyzed on a FACSCalibur instrument with CellQuest software. Dead cells were gated by 1 µg/ml propidium iodide.

2.9. Cytokine production assay

T-cell epitope mapping was performed in mice and monkeys immunized with purified rN (50 and 200 µg, respectively) emulsified in ISA-51 plus 50 µg of the CpG oligonucleotide. Seven days after the second boost, splenocytes from mice or peripheral blood mononuclear cells (PBMCs) from monkeys (4 × 10^5 cells/well) were cultured in RPMI 1640 (GIBCO, San Diego, CA, USA) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml of penicillin, 100 µg/ml of streptomycin, and 50 µg/ml 2-mercaptoethanol with 5 µg/ml of pooled or individual peptides at 37 °C for 5 days. Concanavalin A (Con A) or medium alone served as the positive and background controls, respectively. The supernatant was harvested and assayed for cytokine production. Mouse IFN-γ was quantitated by ELISA using the matching anti-IFN-γ antibody set (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s directions. Monkey IFN-γ was measured using an ELISA kit from Biosource International (Camarillo, CA, USA) according to the manufacturer’s protocol.

All of the animal studies were approved by the Animal Committee of the National Health Research Institutes, Taipei, Taiwan.
2.10. Statistical analysis

Data were evaluated using Student’s t-test analysis of variance (ANOVA) to determine the statistical significance of differences between samples. \( p < 0.05 \) was considered statistically significant.

3. Results and discussion

3.1. N Protein as the target of the SARS candidate vaccine

The ability of certain individuals to overcome infection without treatment led to the hypothesis that administration of vaccines against SARS may provide effective protection against the disease. Like other viruses with spike proteins on the viral surface, coronaviruses have been shown to elicit enhancement of disease through non-neutralizing spike protein-specific antibodies [3], so vaccines that elicit T-cell immunity against SARS proteins are likely to receive more-favorable clinical attention. In animal coronavirus vaccine development, the N protein has been widely tested as an immunogen for protection against coronavirus infections. Inoculation of chickens with plasmid DNA encoding the infectious bronchitis virus (IBV) carboxyl terminus of the N protein led to the induction of a specific cytotoxic T lymphocyte population capable of recognizing two distinct IBV strains. In addition, the adoptive transfer of T cells from animals inoculated with IBV to naive chicks provided CD8+ protection [13]. A Th1 T-cell line resistant to the murine hepatitis virus (MHV) showed marked increases in IFN-\( \gamma \) expression with a decrease in IL-4 production when incubated with MHV-infected cells [14]. Infusion of this resistant cell line into susceptible mice led to complete protection against MHV infection. The immunity against MHV was demonstrated to be a process dependent upon CD8+, perforin, and IFN-\( \gamma \) in the absence of CD4+ T cells [15].

The generation of IgG2a antibodies following DNA immunization of N protein suggested that there was a significant Th1-type response [16]. With the strong potential protective immunity of N protein-based vaccines, we hypothesized that the SARS CoV N protein would elicit effective immune responses against SARS diseases.

3.2. Expression and purification of the recombinant nucleocapsid protein

To aid the downstream purification process, the C-terminal end of the N protein-coding region was tagged with six histidine residues. Expression of rN protein could be induced by adding 1 mM of isopropyl \( \beta \)-\( d \)-thiogalactoside (IPTG) into the E. coli cell culture, and the level of expression was observed using an SDS–PAGE analysis (Fig. 1A, lanes 1 and 2). The electrophoretic position of the rN protein corresponded to the predicted size of 46 kDa. rN proteins were collected as pellets from cell lysates using centrifugation. rN proteins were purified using an IMAC (immobilized metal affinity chromatography) column and by a pH stepwise gradient containing 8 M urea (Fig. 1A, lanes 3–9). Purified rN proteins were refolded by dialysis against PBS and could be detected by blotting with an anti-His antibody (Fig. 1B). We obtained 4–5 mg of purified rN protein from 1 L of cell culture, and it represented a 20% overall yield.

3.3. Immunogenicity of rN protein in mice

As mentioned above, a strong adjuvant that elicits strong cellular immune responses is necessary for the N protein to be effective as a vaccine candidate. Different adjuvant formulations induced different immune responses in immunized animals. To assess the immune responses elicited by the rN protein in our BALB/c mouse model, rN protein was formulated with either incomplete Freund’s adjuvant (IFA), a
potent adjuvant complex, ISA/CpG, or PBS alone. After three immunizations (50 μg of N protein per dose), the N protein-specific antibody responses were measured using ELISA, and results are shown in Fig. 2A. The antibody titers were found to be $8 \times 10^{-8}$, $5 \times 10^{-7}$, and $5 \times 10^{-6}$ in the ISA/CpG, IFA, and PBS groups, respectively. To test whether the strong immune response elicited by the rN protein formulated with ISA/CpG was useful in clinical application, we analyzed the subtypes of reactive antibodies from all groups. The isotypes generated in different groups are shown in Fig. 2B; most of the antibodies were IgG1 found in the PBS group ($1.0 \times 10^{-5}$), with less IgG2a ($1.0 \times 10^{-4}$). There were similar IgG1 titers found in both the IFA and ISA/CpG groups ($3 \times 10^{-6}$). Not surprisingly, the ISA/CpG group generated strong and dominant IgG2a antibodies ($1 \times 10^{-6}$). But the IFA group produced less IgG2a ($6 \times 10^{-5}$). This result indicated that ISA/CpG could drive the immune response toward Th1, and is consistent with previous results which showed that the synthetic oligodeoxynucleotide CpG motif could skew the host’s immune response toward Th1 [17] and the combination of CpG and ISA-51 also showed the ability to enhance the protective efficacy of a subunit malaria vaccine candidate [11].

3.4. Identification of the immunodominant linear B-cell epitopes of NP

Identification of the immunodominant B cell epitopes could be useful for future immunological investigation. To identify B-cell epitopes of the N protein, mice were immunized with N protein formulated with either IFA or ISA/CpG. To systemically analyze the B-cell epitopes, each of the peptide pools (NP1–NP8), consisting of 10 consecutive 15-mer overlapping peptides of the N protein, was used to screen against anti-N antisera (see Table 1). In this peptide-ELISA assay, we used the rN protein as the positive control and internal standard to normalize the reactivity. Since we desired to determine the immunodominant epitopes, mouse sera were diluted to 1:5000 for epitope screening. When mouse antisera were generated from the group immunized with N protein formulated with IFA, we found two major reactive peptide pools to be NP1 and NP8. Further individual peptide reactivity analysis showed that peptides no. 8, 72, 73, 78, and 80 contained immunodominant epitopes (Fig. 3A). In the ISA/CpG-immunized mouse group, NP4 and NPS were the two major reactive peptide pools. With further individual peptide screening, we found the major reactive peptides to be
### Table 1

| Peptide number | 15-mer Amino acid sequence | Pool | Start position |
|----------------|-----------------------------|------|----------------|
| 1              | MSDNGPQSNQRSAPR             | 1    | 1              |
| 2              | PQSNQRSAPRITFGG            | 1    | 6              |
| 3              | RSAPRITFGGPTDST            | 1    | 11             |
| 4              | ITFGGPTDSTDNNQN             | 1    | 16             |
| 5              | PTDSTDNNQNGGRNG            | 1    | 21             |
| 6              | DNNQNGGRNGARPKQ           | 1    | 26             |
| 7              | GGRNGARPKQRRPQG            | 1    | 31             |
| 8              | ARPKQRRPQGLPNNT            | 1    | 36             |
| 9              | LPNNTASWFTALTQH            | 2    | 51             |
| 10             | ASWFTALTQHGKEEL          | 2    | 56             |
| 11             | ALTQHGKEELRFPRG          | 2    | 61             |
| 12             | GKEELRFPRGQGVPI           | 2    | 66             |
| 13             | RFPRGQGVPIASWFT            | 3    | 71             |
| 14             | ASWFTALTQHGKEEL           | 3    | 76             |
| 15             | LPNNTASWFTALTQH            | 4    | 81             |
| 16             | QLPQGTTLPKGFYAEGSRGG      | 4    | 86             |
| 17             | GFYAEQTVKSKHIDAYKTP       | 4    | 91             |
| 18             | KMKELSPRWYFYYLQG          | 5    | 96             |
| 19             | DRLNQLESKVGSDQ            | 5    | 101            |
| 20             | SPRWYFYYLQGTGPEA          | 5    | 106            |
| 21             | FYYLGTGPEASLPYG           | 5    | 111            |
| 22             | TGPEASLPYGANKEG           | 5    | 116            |
| 23             | SLPYGANKEGIVWV            | 5    | 121            |
| 24             | ANKEGIVWVATEGAL           | 5    | 126            |
| 25             | VEGIVWVATEGAL            | 5    | 131            |
| 26             | PEGIVWVATEGAL           | 5    | 136            |
| 27             | VEGIVWVATEGAL           | 5    | 141            |
| 28             | PEGIVWVATEGAL           | 5    | 146            |
| 29             | VEGIVWVATEGAL           | 5    | 151            |
| 30             | PEGIVWVATEGAL           | 5    | 156            |
| 31             | VEGIVWVATEGAL           | 5    | 161            |
| 32             | VEGIVWVATEGAL           | 5    | 166            |
| 33             | VEGIVWVATEGAL           | 5    | 171            |
| 34             | VEGIVWVATEGAL           | 5    | 176            |
| 35             | VEGIVWVATEGAL           | 5    | 181            |
| 36             | VEGIVWVATEGAL           | 5    | 186            |
| 37             | VEGIVWVATEGAL           | 5    | 191            |
| 38             | VEGIVWVATEGAL           | 5    | 196            |
| 39             | VEGIVWVATEGAL           | 5    | 201            |
| 40             | VEGIVWVATEGAL           | 5    | 206            |
| 41             | VEGIVWVATEGAL           | 5    | 211            |
| 42             | VEGIVWVATEGAL           | 5    | 216            |
| 43             | VEGIVWVATEGAL           | 5    | 221            |
| 44             | VEGIVWVATEGAL           | 5    | 226            |
| 45             | VEGIVWVATEGAL           | 5    | 231            |
| 46             | VEGIVWVATEGAL           | 5    | 236            |
| 47             | VEGIVWVATEGAL           | 5    | 241            |
| 48             | VEGIVWVATEGAL           | 5    | 246            |
| 49             | VEGIVWVATEGAL           | 5    | 251            |
| 50             | VEGIVWVATEGAL           | 5    | 256            |
| 51             | VEGIVWVATEGAL           | 5    | 261            |
| 52             | VEGIVWVATEGAL           | 5    | 266            |
| 53             | VEGIVWVATEGAL           | 5    | 271            |
| 54             | VEGIVWVATEGAL           | 5    | 276            |
| 55             | VEGIVWVATEGAL           | 5    | 281            |
| 56             | VEGIVWVATEGAL           | 5    | 286            |
| 57             | VEGIVWVATEGAL           | 5    | 291            |
| 58             | VEGIVWVATEGAL           | 5    | 296            |
| 59             | VEGIVWVATEGAL           | 5    | 301            |
| 60             | VEGIVWVATEGAL           | 5    | 306            |
| 61             | VEGIVWVATEGAL           | 5    | 311            |
| 62             | VEGIVWVATEGAL           | 5    | 316            |
| 63             | VEGIVWVATEGAL           | 5    | 321            |
| 64             | VEGIVWVATEGAL           | 5    | 326            |
| 65             | VEGIVWVATEGAL           | 5    | 331            |
| 66             | VEGIVWVATEGAL           | 5    | 336            |
| 67             | VEGIVWVATEGAL           | 5    | 341            |
| 68             | VEGIVWVATEGAL           | 5    | 346            |
| 69             | VEGIVWVATEGAL           | 5    | 351            |
| 70             | VEGIVWVATEGAL           | 5    | 356            |
| 71             | VEGIVWVATEGAL           | 5    | 361            |
| 72             | VEGIVWVATEGAL           | 5    | 366            |
| 73             | VEGIVWVATEGAL           | 5    | 371            |
| 74             | VEGIVWVATEGAL           | 5    | 376            |
| 75             | VEGIVWVATEGAL           | 5    | 381            |
| 76             | VEGIVWVATEGAL           | 5    | 386            |
| 77             | VEGIVWVATEGAL           | 5    | 391            |
| 78             | VEGIVWVATEGAL           | 5    | 396            |

No. 34, 72, 73, 78, and 80 (Fig. 3A). Regardless of which adjuvants were used, the results showed that BALB/c mouse immunodominant B-cell epitopes were located at the C-terminal regions (peptides no. 72, 73, 78, and 80). However, sera from BALB/c mice immunized with /H9252-propiolactone-inactivated SARS virus recognized the N-terminal region (residues 76–101) of the N protein[18]. These different results could have been due to the nature of the antigens (refolded rN protein versus the inactivated SARS virus) and adjuvants used.

Since the rN protein formulated in ISA/Cpg provided the best immune responses in the mouse model, we selected this adjuvant for the macaque immunogenicity studies. Sera from two immunized macaques both had about a 10$^{-6}$ reactivity titer against the N protein according to ELISA (data not shown). For immunodominant B-cell epitope identification, macaque sera were diluted 1:200 to screen the reactive peptide pools. Serum from monkey no. 1 recognized the peptide pools NP4, NP6, and NP8. Serum from monkey no. 2 reacted with peptide pools NP6 and NP8. To further identify the reactive peptides, we found that peptides no. 54 and 58 contained the immunodominant B-cell epitopes in peptide pool NP6, since they were recognized by the antisera from both macaques. Also peptides no. 72, 73, and 80 in NP8 were found to contain macaque immunodominant B-cell epitopes. Peptides no. 32–34 and 36 in peptide pool NP4 were shown to be most reactive with serum from monkey no. 1 (Fig. 3B). From the results described above, the conserved immunodominant B-cell epitopes in mice and monkeys were located within peptides no. 34 (residues 166–180), 72 (residues 351–365), 73 (residues 356–370), and 80 (residues 396–410).

We further studied the B-cell epitopes of the N protein which recognized SARS patients' sera. When patients' sera were diluted at 1:500 and used to screen the reactive peptide pools, we found that only two patients' sera reacted with peptide pool NP4 and purified NP (data not shown) out of five randomly selected patients' sera. With further individual
peptide screening, the major reactive peptides were found to be peptides no. 32 and 33 that corresponded to residues 156–175 (Fig. 3C). These results were consistent with previous reports by Shichijo et al. [19], He et al. [18], and Guo et al. [20] who also found that the region around residues 156–175 reacted with sera from more than 50% of SARS patients.

We summarized all these data in Fig. 4, which shows that immunodominant B-cell epitopes corresponding to residues 356–375 and 396–410 were conserved in mice and macaques. Interestingly, the region corresponding to residues 156–175 was found to contain B-cell epitopes in all three species. This region (residues 156–175) will be useful for diagnostic kit development and as a biomarker for vaccine development as well.

3.5. Identification of immunodominant T-cell epitopes

Murine T-cell epitopes were identified using the in vitro stimulatory effects of overlapping peptides on T cells derived from splenocytes of BALB/c mice immunized with the N protein formulated with either IFA or ISA/CpG adjuvants. The amounts of secreted IFN-γ in culture supernatants were determined by IFN-γ-specific ELISA kits. No IFN-γ was detected in PBS, which served as the control group (data not shown). As shown in Fig. 5A, IFN-γ production was observed in both IFA- and ISA/CpG-immunized groups, and several different peptides were found to be capable of stimulating IFN-γ secretion. The potential T-cell epitopes were found in the IFA group to correspond to residues 11–30, 36–60, 81–100, and 361–375. In the ISA/CpG group, the T-cell-reactive regions were identified to be residues 1–30, 86–110, 306–320, and 351–365. Only peptides no. 4 (residues 16–40) and 18 (residues 86–100) were found to stimulate IFN-γ production in both immunized groups. Although we could not determine the H-2Kd-restricted CTL epitope from natural SARS CoV infections, it seemed likely that residues 81–95 can be used as an indicator to study the T-cell response of N protein subunit vaccines. Interestingly, peptide no. 18 contains a potential BALB/c mouse CTL epitope, YYRRATRRV, identified by epitope prediction algorithms.

Macaque immunodominant T-cell epitope mapping was also performed with PBMCs isolated from two macaques (M1 and M2) vaccinated twice with the rN protein formulated in ISA/CpG. We found IFN-γ production only in the T-cell culture derived from the PBMCs of M1 (Fig. 5B). In further studies, we observed that only peptide no. 68 (residues 336–350, GAIRKLDKDPQFKD) was capable of
stimulating IFN-γ production in T-cell culture derived from PBMCs of monkey M1. This result could be important information for further SARS vaccine evaluation, especially in a macaque infection model. In our human immunodominant T-cell epitope identification studies (Des et al. published elsewhere), we also found that peptide no. 68 elicited responses from CD4- and CD8-positive cells derived from PBMCs of two SARS patients with the HLA-A11 class I haplotype. Our findings suggest that the rN protein formulated in ISA/CpG adjuvants may play an important role in virus-infected cell clearance.

3.6. Identification of functional CD8+ T-cell epitopes of N protein

In addition to the B-cell and Th1-cell responses, the CTL may play an important role in virus-infected cell clearance. A computer-based program, BIMAS HLA Peptide Binding Prediction program [12], was used to predict candidate CTL peptides of N protein. Two 9-mer peptides (QFKDNVILL and VWVATEGAL) were identified and synthesized based on the highest score value (Table 2). These two peptides and VWVATEGAL were found to be 1.35 and 0.22%, respectively (Fig. 6B). The lower CD8+/IFN-γ+ cell population was perhaps due to peptide 17 being a 15-mer peptide that might not have the best match to the MHC class I preferred peptide length (8–10-mer peptides).

In conclusion, we have demonstrated in mouse and macaque models that the rN protein formulated with potential clinically useful adjuvants, ISA-5 and Cpg, elicited strong Th1 immune responses and may be excellent SARS vaccine candidates. Some of human B- and T-cell immunodominant epitopes of the N protein were also found in mice and macaques immunized with the rN protein formulated in ISA/Cpg adjuvants. The conserved immunodominant epitopes identified in these three species provide very important information for further vaccine design.

Acknowledgment

The financial support from National Science Council of Taiwan (grant # SVAC-12-06) for this study is gratefully acknowledged.

References

[1] Marshall E, Enserink M. Caution urged on SARS vaccines. Science 2004;303(5660):944–6.
[2] Enserink M. One year after outbreak, SARS virus yields some secrets. Science 2004;304(5674):1097.
[3] Yang ZY, Werner HC, Kong WP, Lung K, Traggiai E, Lanzavecchia A, et al. Evasion of antibody neutralization in emerging severe

| Peptide no. | Sequencea | Start position | MHC I peptide binding scoreb |
|-------------|-----------|----------------|-----------------------------|
| 9 mer-1     | QFKDNVILL | 346            | 1382                        |
| 9 mer-2     | VWVATEGAL | 132            | 576                         |
| 17          | PDDQGYYRRATRRV | 81        | 500                         |
| 66          | TP6GTLITSHCAKL | 326       | 460                         |
| 25          | SLPGGAKKEQVWVA | 121        | 345                         |
| 63          | SASAFGGMSRIGMEV | 311       | 120                         |
| 23          | FYYLGTQEPSLPGY | 111        | 120                         |
| 32          | AAVLQQLPGCTTLPK | 156       | 115                         |

a The bold letters represent the computer-predicted H-2Kd-restricted peptide on SARS CoV N protein.

b The score of MHC class I binding peptides were predicted by a computer-based program on the web site of the BioInformatics and Molecular Analysis Section [12].
acute respiratory syndrome coronaviruses. PNAS 2005;102(3):797–801.
[4] Hohdatsu T, Yamato H, Ohkawa T, Kambe M, Matokawa K, Kasahara H, et al. Vaccine efficacy of a cell lysate with recombi-
nant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP. Vet Microbiol 2005;97(1/2):31–44.
[5] Wilson JA, Hart MK. Protection from Ebola virus mediated by cyto-
toxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75(6):2660–4.
[6] Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246(1):134–44.
[7] Fu T-M, Guan L, Friedman A, Schofield TL, Umero JB, Liu MA, et al. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 1999;162(7):4633–70.
[8] Collisson EW, Fuji J, Dzielawa J, Seo SH. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev Comp Immunol 2000;24(2/3):187–200.
[9] Bolla PA, Obrerie MS, Monroe SS, Nix WA, Campagnoli R, Lemmle JE, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300(5624):1394–9.
[10] Kim TW, Lee BH, Hwang CF, Pong S, Rodem R, Wang MC, et al. Generation and characterization of DNA vaccines targeting the nucle-
ocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004;78(9):4636–45.
[11] Kiliaris S, Jones TR, Oakley MS, Zheng H, Kuppasamy SP, Taxy A, et al. CpG oligodeoxynucleotide and montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004;72(2):949–57.
[12] Parker KC, Bodnarchuk MA, Colligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individ-
ual peptide side-chains. J Immunol 1994;152(1):163–75.
[13] Seo SH, Fuji J, Britles WE, Dzielawa J, Collisson EW. Adoptive transfer of infectious bronchitis virus primed [alpha][beta] T cells bearing CD8 antigen protects chicks from acute infection. Virology 2000;269(1):103–9.
[14] Liu MF, Ning Q, Pope M, Moisman T, Zehowitz J, Ding JW, et al. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. Adv Exp Med Biol 1998;440:415–23.
[15] Marion NW, Stohlman SA, Bergmann CC. MBV infection of the CNS: mechanisms of immune-mediated control. Viral Immunol 2001;14(1):1–18.
[16] Hayashi M, Okada F, Ishida K, Maeda A, Kon Y, Motani T, et al. Cytolytic activity induced by intramuscular injection of plasmid DNA expressing the nucleocapsid protein of the IBM strain of mouse hepatitis virus into C57BL/6 mice. J Vet Med Sci 1996;58(8):731–5.
[17] Kleinman DM. Immunotherapeutic uses of CpG oligonucleotides. Nat Rev Immunol 2004;4(4):249–59.
[18] He Y, Zhou H, Wu H, Liu Z, Liu S, Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syn-
drome coronavirus. J Clin Microbiol 2004;42(11):5309–14.
[19] Skibinski S, Keicho N, Long HT, Qiu T, Sun NC, Hsu JD, et al. Assessment of synthetic peptides of severe acute respiratory syn-
drome coronavirus recognized by long-lasting immunity. Tissue Anti-
gens 2004;64(5):600–7.
[20] Gao JP, Petoic M, Campbell W, McGee RL. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 2004;324(2):251–6.